慢性HBV感染者抗-HBc定量检测的临床意义

侯凤琴; 王贵强

doi:10.3969/j.issn.1001-5256.2018.05.001

慢性HBV感染者抗-HBc定量检测的临床意义

DOI: 10.3969/j.issn.1001-5256.2018.05.001

1. 北京大学第一医院感染疾病科暨肝病中心
2. 北京大学国际医院感染肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2685
- HTML全文浏览量: 47
- PDF下载量: 584
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-20
- 出版日期: 2018-05-20

Clinical value of anti-HBc quantification for chronic HBV infection

Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital

摘要

摘要: 作为国家十二五重大专项课题的成果,抗-HBc定量检测技术已经获得上市批准,有望在临床推广应用。我国学者对抗-HBc的临床意义进行了多方面研究探索,研究结果显示了其在慢性HBV感染自然史、基线抗病毒治疗预测等方面具有较好的应用价值。研究发现抗-HBc与ALT呈明显正相关,与肝脏炎症明显相关,尤其在ALT正常慢性HBV感染者中,抗-HBc可以弥补ALT的不足,对此类患者临床治疗决策的制订具有重要意义。
- 肝炎,乙型,慢性 /
- 肝炎抗体,乙型 /
- 丙氨酸转氨酶
Abstract: As the achivement of a major project during the 12 th Five-year Plan Period in China, the technique of anti-HBc quantification has been approved for commercial use and holds promise for wide application in clinical practice. Chinese scholars have explored the clinical significance of anti-HBc in various aspects and found that it has great values in the assessment of natural course of chronic hepatitis B virus ( HBV) infection and the baseline prediction of antiviral therapy. Studies have shown that anti-HBc is significantly positively correlated with alanine aminotransferase ( ALT) and significantly associated with liver inflammation. In chronic HBV infection patients with a normal ALT level, anti-HBc can be used instead as an indicator, with great significance for the development of therapeutic strategy in such patients.
- hepatitis B, chronic /
- hepatitis B antibodies /
- alanine transaminase

HTML全文

参考文献(23)

[1]MARC GG, JAKE TL.Acute viral hepatitis[M].4th Edition.Atlas of Gastroenterology, 2009:623-635.

[2]REHERMANN B, NASCIMBENI M.Immunology of hepatitis B virus and hepatitis C virus infection[J].Nat Rev Immunol, 2005, 5 (3) :215-229.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[4]LI A, YUAN Q, HUANG Z, et al.Novel double-antigen sandwich immunoassay for human hepatitis B core antibody[J].Clin Vaccine Immunol, 2010, 17 (3) :464-469.

[5]Mc MAHON BJ.The natural history of chronic hepatitis B virus infection[J].Hepatology, 2009, 49 (Suppl 5) :s45-s55.

[6]JIA W, SONG LW, FANG YQ, et al.Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B:a prospective observational study[J].Medicine, 2014, 93 (29) :e332.

[7]SONG LW, LIU PG, LIU CJ, et al.Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J].Clin Microbiol Infect, 2015, 21 (2) :197-203.

[8]LI MR, LU JH, YE LH, et al.Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatmentna6ve chronic hepatitis B patients[J].Medicine, 2016, 95 (34) :e4422.

[9] SCHEUER PJ.Classification of chronic viral hepatitis:a need for reassessment[J].J Hepatol, 1991, 13 (3) :372-374.

[10]NGUYEN T, THOMPSON AJ, BOWDEN S, et al.Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:a perspective on Asia[J].J Hepatol, 2010, 52 (4) :508-513.

[11]JAROSZEWICZ J, CALLE SB, WURSTHORN K, et al.Hepatitis B surface antigen (HBs Ag) levels in the natural history of hepatitis B virus (HBV) -infection:a European perspective[J].J Hepatol, 2010, 52 (4) :514-522.

[12]CHAO DT, LIM JK, AYOUB WS, et al.Systematic review with meta-analysis:the proportion of chronic hepatitis B patients with normal alanine transaminase≤40 IU/L and significant hepatic fibrosis[J].Aliment Pharmacol Ther, 2014, 39 (4) :349-358.

[13]ZHOU J, SONG L, ZHAO H, et al.Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis Bpatients with normal alanine aminotransferase[J].Sci Rep, 2017, 7 (1) :2747.

[14]LI MR, ZHENG HW, LU JH, et al.Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-na6ve patients with chronic hepatitis B[J].Oncotarget, 2017, 8 (7) :11063-11070.

[15]FRIED MW, PIRATVISUTH T, LAU GKK, et al.HBe Ag and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBe Ag-positive chronic hepatitis B[J].Hepatology, 2008, 47 (2) :428-434.

[16]MOUCARI R, MACKIEWICZ V, LADA O, et al.Early serum HB-s Ag drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBe Ag-negative patients[J].Hepatology, 2009, 49 (4) :1151-1157.

[17]ZEUZEM S, GANE E, LIAW YF, et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J].J Hepatol, 2009, 51 (1) :11-20.

[18]YUAN Q, SONG LW, LIU CJ, et al.Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients[J].Gut, 2013, 62 (1) :182-184.

[19]FAN R, SUN J, YUAN Q, et al.Baseline quantitative hepatitis Bcore antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos (t) ide analogues[J].Gut, 2016, 65 (2) :313-320.

[20]HOU FQ, SONG LW, YUAN Q, et al.Quantitative hepatitis Bcore antibody level is a new predictor for treatment response in HBe Ag-positive chronic hepatitis B patients receiving peginterferon[J].Theranostics, 2015, 5 (3) :218-226.

[21]XU JH, SONG LW, LI N, et al.Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir[J].J Viral Hepat, 2017, 24 (2) :148-154.

[22]TSENG CH, HSU YC, CHANG CY, et al.Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B[J].J Formos Med Assoc, 2017.[Epub ahead of print]

[23]YUAN G, ZHOU Y, ZHANG H, et al.Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].Int J Clin Exp Med, 2015, 8 (8) :13524-13531.

施引文献

资源附件(0)

访问统计